Transinsight Wins FutureSAX VC-Forum for Best Company

TransinsightFutureSAX invited venture capitalists and entrepreneurs from all over Germany to Dresden under the motto "Lift Off with Venture Capital - Emphasis on Technology and Environment." In front of 80 guests, among them 30 investors, the jury selected Transinsight with its software technology for knowledge-based information searches from seven finalists as the winner of the most promising investment.

"The jury choose the Transinsight team because of their excellent business concept and investment, as well as their convincing presentation", says futureSAX representative Kerstin Trautmann. She goes on to say: "the Businessplan-Wettbewerb Sachsen GmbH congratulates the winner for this outstanding success."

"We are proud our concept is regarded as outstanding by top-class investors", says Dr. Michael R. Alvers, CEO of Transinsight GmbH. He continues: "We created software with the potential to revolutionize information searching. Themed "Together we Search, Think, and Write", we raise searching to a new level. We do not rank search results, the user does! This fosters democracy and allows companies and others to save plenty of time, which then becomes available for other relevant tasks."

Mark Miller, CEO of CatCap and a member of the jury, is convinced that close cooperation between the university and new high-tech companies in Dresden will lead to success. "Transinsight GmbH, with its brand new search paradigm, is well-positioned in the rapidly growing information handling and knowledge management market," says Miller.

Related news articles:

About Transinsight
Founded in 2005, Transinsight is focused on software solutions for the life sciences providing products for knowledge-based technologies. The flagship product, www.gopubmed.com, a well established biomedical search engine, is the first knowledge-based search engine for the Life Sciences on the Internet. Transinsight is headquartered in one of the leading German biotech incubators, the BioInnovationCenter Dresden BIOZ, where science and business work under one roof. Transinsight works in close collaboration with the Technical University Dresden. For further information, visit www.transinsight.com.

About the VC Forum futureSAX
FutureSAX hosted a venture capital forum near the Frauenkirche for intensive discourse between venture capital investors. This forum has been the only VC networking forum to date in Saxony. Companies in the fields of technology and environment from all over Germany looking for investors could apply for one of eight presentation slots. FutureSAX was supported by KPMG and 3i Deutschland GmbH as well as by cooperation partners CatCap GmbH, Neuhaus Partners GmbH, and F.A.Z.-Institut GmbH. Investors were given the chance to get to know different outstanding companies during a single day as well as to get in contact with many potential co-investors. Companies were given the opportunity to present themselves in front of a community of investors. After the presentations, companies and investors got together over refreshments for one-on-one discussions. For further information, visit www.futuresax.de.

Most Popular Now

ChatGPT Extracts Data for Ischaemic Stro…

In an ischaemic stroke, an artery in the brain is blocked by blood clots and the brain cells can no longer be supplied with blood as a result. Doctors must...

Herefordshire and Worcestershire Health …

Herefordshire and Worcestershire Health and Care NHS Trust has successfully implemented Alcidion's Miya Precision platform to streamline bed management workflow across seven community hospitals in Worcestershire. The trust delivers community...

A Shortcut for Drug Discovery

For most human proteins, there are no small molecules known to bind them chemically (so called "ligands"). Ligands frequently represent important starting points for drug development but this knowledge gap...

New Horizon Europe Funding Boosts Europe…

The European Commission has announced the launch of new Horizon Europe calls, with a substantial funding pool of over €112 million. These calls are aimed primarily at pioneering projects in...

Cleveland Clinic Study Finds AI can Deve…

Cleveland Clinic researchers developed an artficial intelligence (AI) model that can determine the best combination and timeline to use when prescribing drugs to treat a bacterial infection, based solely on...

New AI-Technology Estimates Brain Age Us…

As people age, their brains do, too. But if a brain ages prematurely, there is potential for age-related diseases such as mild-cognitive impairment, dementia, or Parkinson's disease. If "brain age...

With Huge Patient Dataset, AI Accurately…

Scientists have designed a new artificial intelligence (AI) model that emulates randomized clinical trials at determining the treatment options most effective at preventing stroke in people with heart disease. The model...

Radboud University Medical Center and Ph…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Radboud University Medical Center have signed a hospital-wide, long-term strategic partnership that delivers the latest patient monitoring...

GPT-4, Google Gemini Fall Short in Breas…

Use of publicly available large language models (LLMs) resulted in changes in breast imaging reports classification that could have a negative effect on patient management, according to a new international...

ChatGPT fails at heart risk assessment

Despite ChatGPT's reported ability to pass medical exams, new research indicates it would be unwise to rely on it for some health assessments, such as whether a patient with chest...

Study Shows ChatGPT Failed when Challeng…

With artificial intelligence (AI) poised to become a fundamental part of clinical research and decision making, many still question the accuracy of ChatGPT, a sophisticated AI language model, to support...

Virtual Reality Shows Promise in Fightin…

A new study published in JMIR Mental Health sheds light on the promising role of virtual reality (VR) in treating major depressive disorder (MDD). Titled "Examining the Efficacy of Extended...